{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:30:01Z","timestamp":1790418601568,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1097\/md.0000000000005023","type":"journal-article","created":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T09:47:24Z","timestamp":1475142444000},"page":"e5023","source":"Crossref","is-referenced-by-count":8,"title":["Predictive factors for anti-HBs status after 1 booster dose of hepatitis B vaccine"],"prefix":"10.1097","volume":"95","author":[{"given":"I-Cheng","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Chu Yen","family":"Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daw-Shyong","family":"Perng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Yi","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-84-20210309","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.3748\/wjg.v17.i25.3054","article-title":"Epidemiological and clinical features of hepatitis B virus related liver failure in China","volume":"17","author":"Liu","year":"2011","journal-title":"World J Gastroenterol"},{"key":"R2-84-20210309","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.3748\/wjg.v17.i44.4853","article-title":"Hepatitis B virus infection and the risk of hepatocellular carcinoma","volume":"17","author":"Tan","year":"2011","journal-title":"World J Gastroenterol"},{"key":"R3-84-20210309","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.3748\/wjg.v19.i24.3861","article-title":"Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations","volume":"19","author":"Yang","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R4-84-20210309","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2893.2011.01577.x","article-title":"Hepatocellular carcinoma screening practices and impact on survival among hepatitis B-infected Asian Americans","volume":"19","author":"Sarkar","year":"2012","journal-title":"J Viral Hepatitis"},{"key":"R5-84-20210309","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cld.2013.05.002","article-title":"HBV infection and hepatocellular carcinoma","volume":"17","author":"Iavarone","year":"2013","journal-title":"Clin Liver Dis"},{"key":"R6-84-20210309","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1126\/science.8211155","article-title":"From hepatitis to hepatoma: lessons from type B viral hepatitis","volume":"262","author":"Chen","year":"1993","journal-title":"Science (New York, NY"},{"key":"R7-84-20210309","doi-asserted-by":"crossref","first-page":"e2758","DOI":"10.1097\/MD.0000000000002758","article-title":"The epidemiological investigation on the risk factors of hepatocellular carcinoma: a case-control study in southeast China","volume":"95","author":"Niu","year":"2016","journal-title":"Medicine"},{"key":"R8-84-20210309","doi-asserted-by":"crossref","first-page":"e3284","DOI":"10.1097\/MD.0000000000003284","article-title":"The hepatitis viral status in patients with hepatocellular carcinoma: a study of 3843 patients from Taiwan Liver Cancer Network","volume":"95","author":"Chang","year":"2016","journal-title":"Medicine"},{"key":"R9-84-20210309","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MD.0b013e3181c10477","article-title":"Independent and additive interactive effects among tumor necrosis factor-alpha polymorphisms, substance use habits, and chronic hepatitis B and hepatitis C virus infection on risk for hepatocellular carcinoma","volume":"88","author":"Jeng","year":"2009","journal-title":"Medicine"},{"key":"R10-84-20210309","first-page":"152","article-title":"Hepatitis B virus infection","volume":"76","author":"Margolis","year":"1998","journal-title":"Bull World Health Organ"},{"key":"R11-84-20210309","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cld.2013.05.001","article-title":"Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B","volume":"17","author":"Asselah","year":"2013","journal-title":"Clin Liver Dis"},{"key":"R12-84-20210309","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cld.2013.05.005","article-title":"Impact of therapy on the long-term outcome of chronic hepatitis B","volume":"17","author":"Liaw","year":"2013","journal-title":"Clin Liver Dis"},{"key":"R13-84-20210309","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJM198010093031501","article-title":"Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States","volume":"303","author":"Szmuness","year":"1980","journal-title":"N Engl J Med"},{"key":"R14-84-20210309","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0140-6736(81)91908-5","article-title":"Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal)","volume":"1","author":"Maupas","year":"1981","journal-title":"Lancet (London, England"},{"key":"R15-84-20210309","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1473-3099(02)00315-8","article-title":"Global control of hepatitis B virus infection","volume":"2","author":"Kao","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"R16-84-20210309","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.socscimed.2013.11.028","article-title":"The pharmaceuticalization of sexual risk: vaccine development and the new politics of cancer prevention","volume":"101","author":"Mamo","year":"2014","journal-title":"Soc Sci Med (1982"},{"key":"R17-84-20210309","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0140-6736(83)90624-4","article-title":"Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine","volume":"2","author":"Beasley","year":"1983","journal-title":"Lancet"},{"key":"R18-84-20210309","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/jvh.12102","article-title":"Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial","volume":"20","author":"Pande","year":"2013","journal-title":"J Viral Hepatitis"},{"key":"R19-84-20210309","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/INF.0b013e31817702ba","article-title":"Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study","volume":"27","author":"Bialek","year":"2008","journal-title":"Pediatric Infect Dis"},{"key":"R20-84-20210309","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1086\/587695","article-title":"Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization","volume":"197","author":"Lu","year":"2008","journal-title":"J Infect Dis"},{"key":"R21-84-20210309","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vaccine.2013.10.074","article-title":"Hepatitis B vaccination of adolescents: significance of non-protective antibodies","volume":"32","author":"Chiara","year":"2013","journal-title":"Vaccine"},{"key":"R22-84-20210309","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hep.25988","article-title":"Chronic hepatitis B infection in adolescents who received primary infantile vaccination","volume":"57","author":"Wu","year":"2013","journal-title":"Hepatology (Baltimore, MD"},{"key":"R23-84-20210309","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.510290349","article-title":"Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen","volume":"29","author":"Huang","year":"1999","journal-title":"Hepatology (Baltimore, MD"},{"key":"R24-84-20210309","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(05)67568-X","article-title":"Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study","volume":"366","author":"Zanetti","year":"2005","journal-title":"Lancet (London, England"},{"key":"R25-84-20210309","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1016\/j.vaccine.2007.06.059","article-title":"Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years","volume":"25","author":"Hammitt","year":"2007","journal-title":"Vaccine"},{"key":"R26-84-20210309","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/hep.20490","article-title":"Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination","volume":"40","author":"Lu","year":"2004","journal-title":"Hepatology (Baltimore, MD"},{"key":"R27-84-20210309","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1016\/j.vaccine.2012.08.067","article-title":"Efficacy of yeast-derived recombinant hepatitis B vaccine after being used for 12 years in highly endemic areas in China","volume":"30","author":"Shen","year":"2012","journal-title":"Vaccine"},{"key":"R28-84-20210309","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.vaccine.2012.10.101","article-title":"Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17\u201318 November 2011","volume":"31","author":"FitzSimons","year":"2013","journal-title":"Vaccine"},{"key":"R29-84-20210309","doi-asserted-by":"crossref","first-page":"8085","DOI":"10.1016\/j.vaccine.2007.09.013","article-title":"Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination","volume":"25","author":"Su","year":"2007","journal-title":"Vaccine"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000005023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:34:43Z","timestamp":1620959683000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201609270-00084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":29,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000005023","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}